|
Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO). |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Mundipharma |
Other Relationship - Lilly |
|
|
Honoraria - Astellas Pharma; EUSA Pharma |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); MSD (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche |
|
|
|
Consulting or Advisory Role - Ipsen; MSD; Sanofi |
Research Funding - Janssen (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer/Ipsen |
|
|
Consulting or Advisory Role - Astellas Pharma; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; PFIZER; Roche/Genentech; Sanofi/Aventis |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IPSEN; Janssen-Cilag; MSD Oncology; Pfizer; Roche/Genentech; Sanofi/Aventis |
|
|
Travel, Accommodations, Expenses - Ipsen; Roche |
|
|
Consulting or Advisory Role - Amgen; amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; Janssen-Cilag; pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi |
Research Funding - Ipsen; Sanofi |
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche |